Agilent Technologies, Inc. · NYSE:A
Agilent Technologies — Q3 2017 Earnings Presentation
10 slides from Agilent Technologies's earnings presentation, August 2017
Slide 1: Agilent Technologies Q3'17 Results Presentation
Agilent Technologies Q3'17 Results Presentation
Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements (including, without limitation, information and future guidance on the company’s goals, priorities, revenues, operating profit and operating margin, growth opportunities, customer service and innovation plans, new product introduction
Slide 3: Agilent Results Q3'17
Agilent Results Q3'17 Scale and leading technology across Analytical Laboratories and Clinical & Dx markets Q3'17 Financial Metrics Q3'17 Headlines • Revenues: $1.11B, +7.5% y/y core(1)(2),+6.7% • Growth: Second consecutive quarter of double- reported (+0.1% M&A, -0.9% FX). Core growth digit Chemica
Slide 4: Life Sciences & Applied Markets Group (LSAG)
Life Sciences & Applied Markets Group (LSAG) • Strong core revenue growth led by demand Instrumentation and Informatics for Analytical Laboratories in Europe and China. Chem & Energy, Environmental and Pharma drove the results, with gains across the product portfolio. • Operating Margin for the quar
Slide 5: Cross Lab Group (ACG)
Agilent Cross Lab Group (ACG) Analytical Laboratory • Continued strong revenue performance. Consumables and Services Gains across all end-markets were led by double digit growth in Academia & Government and Pharma. Growth was robust for both services and consumables. • Operating Margin in the quarte
Slide 6: Diagnostics and Genomics Group (DGG)
Diagnostics and Genomics Group (DGG) • Solid growth performance across markets and Pathology, Genomics, and Nucleic Acid Manufacturing regions led by strength in Pathology, Companion Diagnostics and Nucleic Acid Solutions. Asia ex- Japan and Europe led regional gains. • Operating Margin for the quar
Slide 7: Growth in a $50B Market – Q3'17 Results by End Market
Growth in a $50B Market – Q3'17 Results by End Market Gains across end markets highlighted by robust Pharma and Chemical/Energy results and a return to growth for A&G Analytical Laboratory End Markets Agilent Revenue by End Market (1) Q3'17 revenues: +8% y/y on core(2) basis Pharma & Biotech: Up
Slide 8: Profitable Growth Plan
Agilent Profitable Growth Plan Recent Actions Delivering on “Agile Agilent” Initiatives • Multi-year program to increase efficiency and customer focus. Operating Margin up year-over-year – 10th consecutive quarter. Portfolio Investments and “Go-to-Market” Capability • Acquired Cobalt Light Syste
Slide 9: Strategy to Win
Agilent Strategy to Win Creating shareholder value Above Market Growth • Innovative, highly differentiated new products and solutions • Win enterprise lab-wide services & consumables - CrossLab • Accelerate bio-pharma penetration • Drive adoption of clinical genomics applications Aggressively ex
Slide 10: Q4'17 and FY17 Guidance and Forward-looking Considerations
Q4’17 and FY17 Guidance and Forward-looking Considerations Based on July 31, 2017 Exchange Rates FY17 FY17 Guidance FY16 Guidance at • Revenue: $4.435B - $4.455B: growth at mid-point 6% core(4), 5.8% (2) mid-point Actual reported (1) (+0.3% M&A, -0.5% FX) (1)(2) • Operating Margin: 21.5% at mid-poin